Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to improve patient care and transform treatment paradigms [1][3] - The company will present at the Morgan Stanley Global Healthcare Conference on September 10, 2025, at 10:50 am PT / 1:50 pm ET [2] Company Overview - Sight Sciences develops minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The OMNI® Surgical System and OMNI® Edge Surgical System are implant-free technologies for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical System is a bladeless device for excising trabecular meshwork in ophthalmic procedures [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]

Core Insights - Sight Sciences, Inc. reported second-quarter financial results for 2025, showing a revenue of $19.6 million, an 8% decrease year-over-year, and raised its revenue guidance for the full year 2025 [1][5][12] - The company emphasized strong execution and growth momentum in surgical glaucoma accounts and procedural utilization, reinforcing its market leadership in implant-free minimally invasive glaucoma surgery (MIGS) [4][21] Financial Performance - Revenue for Q2 2025 was $19.6 million, down 8% from $21.4 million in Q2 2024; Surgical Glaucoma revenue was $19.2 million, a 5% decrease, while Dry Eye revenue fell to $0.3 million from $1.1 million [5][7][30] - Gross profit for Q2 2025 was $16.6 million, with a gross margin of 85%, slightly down from 86% in the prior year [6][8] - Total operating expenses decreased by 9% to $28.3 million, with selling, general, and administrative expenses down 11% to $23.9 million [9][10] Clinical Developments - The company announced the publication of 24-month results from the SAHARA randomized controlled trial, demonstrating the effectiveness of the TearCare System for treating dry eye disease [7] - A cost-utility analysis showed that TearCare is more cost-effective than cyclosporine 0.05% for treating moderate to severe meibomian gland disease associated with dry eye disease [7] Guidance and Future Outlook - The company raised its revenue guidance for full year 2025 to a range of $72.0 million to $76.0 million, reflecting a 5% to 10% decline compared to 2024 [12] - Adjusted operating expenses guidance for 2025 remains at $101.0 million to $105.0 million, indicating a potential increase of 0% to 4% compared to 2024 [12] Market Position and Strategy - Surgical Glaucoma ordering accounts reached an all-time high of 1,174, up 4% from the previous year, indicating growing market penetration [7] - The company continues to focus on innovative technologies to enhance patient outcomes and elevate the standard of care for glaucoma and dry eye disease management [4][21]

Core Insights - The cost-utility analysis (CUA) indicates that the TearCare System is more cost-effective and offers better health utility compared to cyclosporine 0.05% (CsA) for treating moderate to severe meibomian gland disease (MGD) associated dry eye disease (DED) [1][2][3] Cost-Effectiveness Analysis - TearCare resulted in lower annual costs of $4,916 per patient compared to $5,819 for CsA, leading to annual cost savings of $903 [2][8] - TearCare also provided a higher quality-adjusted life year (QALY) of 0.76 versus 0.74 for CsA, translating to an incremental benefit of 0.014 QALYs [2][8] Clinical and Economic Implications - The analysis supports the notion that TearCare not only enhances patient outcomes but also represents a more economically sustainable approach to managing MGD-associated DED, with significant cost savings noted [3][5] - The findings are expected to bolster efforts to increase patient access to interventional dry eye therapies like TearCare [5] Robustness of Results - Scenario analyses confirmed the robustness of the results, showing consistent cost savings and greater QALY gains for TearCare even with varying assumptions [8]

Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at the Stifel 2025 Virtual Ophthalmology Forum on May 27, 2025 [2] Company Overview - Sight Sciences specializes in minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The OMNI® Surgical System and OMNI® Edge Surgical System are implant-free technologies for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical System is a bladeless device for excising trabecular meshwork in ophthalmic procedures [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease, addressing the leading cause of dry eye [3]

Core Viewpoint - Sight Sciences, Inc. is set to report its financial results for Q1 2025 on May 8, 2025, with a conference call scheduled to discuss the results [1] Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative interventional solutions to improve patient care and address prevalent eye diseases [3] - The company's OMNI® Surgical System is designed for glaucoma surgery, indicated for reducing intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical Instrument is a bladeless device used in ophthalmic procedures to excise trabecular meshwork [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]

MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very ...